| A distinct “side population” of cells with high drug efflux capacity in human tumor cells C Hirschmann-Jax, AE Foster, GG Wulf, JG Nuchtern, TW Jax, U Gobel, ... Proceedings of the National Academy of Sciences 101 (39), 14228-14233, 2004 | 1717 | 2004 |
| In Vivo Biodistribution of Nanoparticles JPM Almeida, AL Chen, A Foster, R Drezek Nanomedicine 6 (5), 815-835, 2011 | 641 | 2011 |
| T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ... Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009 | 602 | 2009 |
| Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b JA Craddock, AN Lu, A Bear, M Pule, MK Brenner, CM Rooney, AE Foster Journal of immunotherapy 33 (8), 780-788, 2010 | 594 | 2010 |
| Sox9 and NFIA coordinate a transcriptional regulatory cascade during the initiation of gliogenesis P Kang, HK Lee, SM Glasgow, M Finley, T Donti, ZB Gaber, BH Graham, ... Neuron 74 (1), 79-94, 2012 | 379 | 2012 |
| Improving T cell therapy for cancer AM Leen, CM Rooney, AE Foster Annu. Rev. Immunol. 25 (1), 243-265, 2007 | 314 | 2007 |
| Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease B Savoldo, CM Rooney, A Di Stasi, H Abken, A Hombach, AE Foster, ... Blood, The Journal of the American Society of Hematology 110 (7), 2620-2630, 2007 | 299 | 2007 |
| Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor AE Foster, G Dotti, A Lu, M Khalil, MK Brenner, HE Heslop, CM Rooney, ... Journal of immunotherapy 31 (5), 500-505, 2008 | 261 | 2008 |
| Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and … AA Kennedy-Nasser, S Ku, P Castillo-Caro, Y Hazrat, MF Wu, H Liu, ... Clinical Cancer Research 20 (8), 2215-2225, 2014 | 236 | 2014 |
| Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes C Quintarelli, JF Vera, B Savoldo, GMP Giordano Attianese, M Pule, ... Blood, The Journal of the American Society of Hematology 110 (8), 2793-2802, 2007 | 212 | 2007 |
| In vivo gold nanoparticle delivery of peptide vaccine induces anti‐tumor immune response in prophylactic and therapeutic tumor models JPM Almeida, AY Lin, ER Figueroa, AE Foster, RA Drezek Small 11 (12), 1453-1459, 2015 | 184 | 2015 |
| Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy AY Lin, JP Mattos Almeida, A Bear, N Liu, L Luo, AE Foster, RA Drezek PloS one 8 (5), e63550, 2013 | 179 | 2013 |
| Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation K Micklethwaite, A Hansen, A Foster, E Snape, V Antonenas, M Sartor, ... Biology of Blood and Marrow Transplantation 13 (6), 707-714, 2007 | 167 | 2007 |
| Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer AS Bear, LC Kennedy, JK Young, SK Perna, JP Mattos Almeida, AY Lin, ... PloS one 8 (7), e69073, 2013 | 158 | 2013 |
| A distinct “side population” of cells in human tumor cells: implications for tumor biology and therapy C Hirschmann-Jax, AE Foster, GG Wulf, MA Goodell, MK Brenner Cell Cycle 4 (2), 206-208, 2005 | 141 | 2005 |
| Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes Y Nakazawa, LE Huye, G Dotti, AE Foster, JF Vera, PR Manuri, CH June, ... Journal of immunotherapy 32 (8), 826-836, 2009 | 140 | 2009 |
| T cells enhance gold nanoparticle delivery to tumors in vivo LC Kennedy, AS Bear, JK Young, NA Lewinski, J Kim, AE Foster, ... Nanoscale research letters 6, 1-11, 2011 | 127 | 2011 |
| Human CD62L–memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion AE Foster, M Marangolo, MM Sartor, SI Alexander, M Hu, KF Bradstock, ... Blood 104 (8), 2403-2409, 2004 | 123 | 2004 |
| Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7 JF Vera, V Hoyos, B Savoldo, C Quintarelli, GMPG Attianese, AM Leen, ... Molecular Therapy 17 (5), 880-888, 2009 | 106 | 2009 |
| Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40 AE Foster, A Mahendravada, NP Shinners, WC Chang, J Crisostomo, ... Molecular therapy 25 (9), 2176-2188, 2017 | 100 | 2017 |
Helen HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and TexasGeverifieerd e-mailadres voor bcm.edu
